Steve Schonfeld’s CRISPR Therapeutics CRSP Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$2.18M Buy
+39,450
New +$2.13M 0.01% 1100
2024
Q4
– Sell
-24,193
Closed -$1.14M – 2072
2024
Q3
$1.14M Buy
+24,193
New +$1.23M 0.01% 1119
2024
Q1
– Sell
-17,228
Closed -$1.08M – 2119
2023
Q4
$1.08M Buy
+17,228
New +$952K 0.01% 1007
2022
Q4
– Sell
-17,567
Closed -$1.15M – 2659
2022
Q3
$1.15M Buy
+17,567
New +$1.27M 0.01% 1176
2021
Q3
– Sell
-10,271
Closed -$1.66M – 2205
2021
Q2
$1.66M Buy
+10,271
New +$1.25M 0.02% 773
2020
Q2
– Sell
-8,600
Closed -$365K – 1288
2020
Q1
$365K Buy
+8,600
New +$444K 0.02% 681
2019
Q4
– Sell
-26,420
Closed -$1.08M – 1313
2019
Q3
$1.08M Buy
+26,420
New +$1.26M 0.03% 452
2018
Q4
– Sell
-13,700
Closed -$607K – 1086
2018
Q3
$607K Buy
+13,700
New +$717K 0.03% 538

Other funds holding CRSP

Steve Schonfeld's CRSP Position: Q3 2026 in Review

Steve Schonfeld opened a new position in CRISPR Therapeutics (CRSP) in Q3 2026: 39,450 shares worth $2.18M. The stake represents 0.01% of the portfolio and ranks #1100 among its holdings. This is a return to the name: Steve Schonfeld previously reported a position in CRSP as recently as Q3 2024.

Steve Schonfeld first reported a position in CRSP in Q3 2018 and has held it in 8 quarters since. 504 funds tracked by Wall St. Rank hold CRSP as of Q3 2026.

  • Steve Schonfeld held 39,450 shares of CRISPR Therapeutics worth $2.18M as of Q3 2026.
  • CRISPR Therapeutics was a new Steve Schonfeld position in Q3 2026.
  • CRISPR Therapeutics made up 0.01% of Steve Schonfeld's portfolio in Q3 2026, its #1100 holding.
  • Steve Schonfeld first reported a position in CRISPR Therapeutics in Q3 2018 and has held it in 8 quarters since.
  • 504 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q3 2026.

Based on Schonfeld Strategic Advisors's 13F filing for Q3 2026, filed 16 Nov 2026.